Global life sciences company Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc, a UK-based diagnostics developer, on Tuesday announced the successful completion of an evaluation program for specific monoclonal antibodies targeting Cizzle's CIZ1B cancer biomarker. The evaluation aimed to assess the feasibility of using ProteinSimple's Simple Western platform (a Bio-Techne brand) for high-throughput detection of the CIZ1B cancer biomarker, potentially aiding in early-stage lung cancer detection.

The global lung cancer screening market is expected to grow from USD2.80bn in 2021 to USD4.85bn in 2028, with a projected CAGR of 8.1% during the forecast period. Additionally, updated lung cancer screening guidelines in 2021 by the United States Preventive Services Task Force (USPSTF) have expanded eligibility, potentially saving thousands of lives each year.

Cizzle Biotechnology, founded in 2006 as a spin-out from the University of York, is working on a blood test for early lung cancer detection. Its prototype test focuses on identifying the CIZ1B biomarker, a stable plasma biomarker variant highly correlated with early-stage lung cancer. This innovative approach has the potential to significantly impact cancer diagnosis.

Bio-Techne Corporation offers tools and bioactive reagents for research and clinical diagnostics. Its products support scientific investigations, drug discovery and accurate clinical tests. With a diverse product portfolio, Bio-Techne reported approximately USD1.1bn in net sales in fiscal 2023 and employs around 3,200 professionals worldwide.